3Q26 Revenue Up Modestly
发布时间:2026-11-02 来源:华泰证券
Yunnan Baiyao reported 9M26 revenue/the attributable net profit/recurring net profit of RMB32.26/4.82/4.63bn (+5.2/+0.9/+1.8% YoY). For 3Q26, revenue/the attributable net profit/recurring net profit came in at RMB10.37/1.12/1.11bn (+10.4/-2.0/+2.2% YoY). Against a challenging backdrop across pharmacies, healthcare, distribution, and retail, Yunnan Baiyao delivered steady results. We expect the company to keep strengthening its core business and improving quality and efficiency. Maintain OVERWEIGHT.
Industrial and commercial revenue grew at a single-digit pace
We estimate 9M26 industrial revenue rose by a single-digit percentage YoY: 1) the pharmaceutical business group posted high-single-digit revenue growth, with steady growth in the Baiyao series and continued breakthroughs from single products in the generic drug series; 2) the health products subsidiary delivered stable results; 3) external sales at the TCM resources business group declined slightly, mainly due to lower TCM raw material prices. We estimate 9M26 revenue at the provincial pharmaceutical company grew by a single-digit percentage YoY, driven by solid performance in non-drug distribution and hospital-adjacent stores.
Expense ratios improving; working capital metrics stay solid
1) In 9M26, the selling, administrative, and R&D expense ratios were 11.3%, 1.6%, and 0.9%, respectively (-0.9pp, -0.2pp, +0.1pp YoY). 2) At end-9M26, notes and accounts receivable stood at RMB11.7bn (+RMB0.8bn QoQ), inventory at RMB6.3bn (+RMB0.1bn QoQ), and cash plus trading financial assets at RMB14.3bn (-RMB1.2bn QoQ). The asset-liability ratio was 26%, indicating a healthy asset structure. 3) Operating cash flow reached RMB4.9bn, equivalent to 101% of net profit over the same period, reflecting solid cash generation. 4) Weighted average ROE was 11.8%.
TCM, chemical, and biologic drug R&D advance in parallel
Yunnan Baiyao continues to step up R&D investment, with 9M26 R&D spending of RMB340mn (+24% YoY): 1) Near term: secondary development of 24 major TCM products (including Baiyao aerosol, Baiyao capsules, Qixuekang, and Gongxuening), with 53 ongoing projects. 2) Medium term: Quansanqi tablets have completed Phase II trials; Fugu Guben ointment has initiated Phase III; flurbiprofen has completed BE studies; loxoprofen sodium BE studies are underway. 3) Long term: INR101 (diagnostic radiopharmaceutical) has initiated Phase III trials; INR102 (therapeutic radiopharmaceutical) has completed Phase I enrollment and more than half of Phase IIa sites have been activated; the IND for INR301 (monoclonal antibody) has been accepted by both the NMPA and FDA, and a Phase I trial in China has started. 4) The company announced plans to inject RMB50mn of its own funds into Tianjin Yunhe Pharmaceutical, a wholly-owned subsidiary established in 2023 to handle R&D and commercialization of innovative radiopharmaceuticals. We believe this capital increase reflects the company's confidence in the prospects of its radiopharmaceutical pipeline.
Earnings forecasts and valuation
We maintain our earnings forecasts. We expect attributable net profit of RMB5.53/5.99/6.41bn in 2026/2027/2028 (+7/+8/+7% YoY). We apply a 21x 2027E PE to derive our target price of RMB70.50 (previous: RMB74.45, based on 24x 2026E profit of RMB5.53b), above its peers' average of 18x on Wind consensus given the company's diversification. Maintain OVERWEIGHT.
Risks: weakening pharmacy industry sentiment, VBP policy outcomes falling short of our expectations, and slower M&A integration than we expect.